Retatrutide (LY3437943) is a single peptide that activates three hormone receptors at once: GIP, GLP-1 and glucagon. GIP and GLP-1 are the incretin pathways behind the current generation of weight-management compounds. Adding glucagon receptor activity is designed to raise energy expenditure on top of reducing appetite.
In a 48-week phase 2 trial published in the New England Journal of Medicine in 2023, participants on the highest dose lost an average of 24.2% of their body weight. Retatrutide has since moved into phase 3 trials.
Each NW Supplements pen is pre-mixed and pre-filled, so there is nothing to reconstitute and no separate kit to buy. Every pen is genuine Alluvi Healthcare stock, manufactured in Germany, with its batch number and expiry date printed on the box.
